Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.

For the first time in over a decade, obesity rates have dropped in the United States. A recent study by the CDC showed that ...

The US Food and Drug Administration has approved ... "Today's approval offers adults with obesity or overweight a beneficial new treatment option to incorporate into a weight management program ...

There’s still scope for a new generation of drugs to replace weight-loss market leaders like Novo Nordisk A/S’s Wegovy, ...

Can weight loss drugs curb alcohol addictions? This Louisiana doctor is keeping an eye on new findings and emerging research.

The new classes of obesity medications—GLP-1 and GLP ... than one-third of patients given Wegovy or a similar drug at some point in 2021 were still on them a year later. It’s not known what ...

America's screwed-up healthcare system is preventing millions from receiving a new ... loss drugs, which also includes the buzzy Ozempic, that represents a watershed moment for obesity treatment.

Telehealth company Ro will offer single-dose vials of Eli Lilly's obesity therapy Zepbound in an expansion of the ways patients with a prescription can access the drug. The agreement means Ro has ...

The start of mid-stage testing of PF-07081532 triggers a $10 million milestone payment to Sosei Heptares, which has been working with Pfizer on small-molecule drugs directed at G protein-coupled ...

Across a sample of nearly 17 million adults in a new JAMA Health Forum study, mean population body mass index grew from 2013 to 2021 ... loss drugs like Ozempic are linked to a lower obesity ...

a new study finds. Data on almost 17 million adults nationwide showed the obesity rate -- which has been rising for years -- fell from 46.2% of adults in 2021 to 45.6% in 2023, Harvard University ...